Stockscreener 앱 받기
1.58
4.24%
-0.07
시간 외 거래:
1.58
전일 마감가:
$1.65
열려 있는:
$1.62
하루 거래량:
37,406
Relative Volume:
0.44
시가총액:
$141.46M
수익:
$5.15M
순이익/손실:
$-65.35M
주가수익비율:
-1.1704
EPS:
-1.35
순현금흐름:
$-20.85M
1주 성능:
+6.20%
1개월 성능:
+8.22%
6개월 성능:
-5.67%
1년 성능:
-22.93%
1일 변동 폭
$1.5715
$1.65
1주일 범위
$1.41
$1.65
52주 변동 폭
$1.10
$2.43
Cellectis Adr Stock (CLLS) Company Profile
CLLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
1.58 | 141.46M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2022-05-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Robert W. Baird | Outperform |
| 2020-03-06 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-10-30 | 재개 | Guggenheim | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-05-24 | 재개 | Citigroup | Neutral |
| 2019-03-14 | 개시 | William Blair | Outperform |
| 2018-12-19 | 개시 | Goldman | Neutral |
| 2018-07-16 | 개시 | Barclays | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2017-09-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2017-09-05 | 재확인 | Wells Fargo | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-02-28 | 개시 | Wells Fargo | Outperform |
| 2016-04-05 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | 개시 | BofA/Merrill | Buy |
| 2015-04-20 | 개시 | Jefferies | Buy |
| 2015-04-20 | 개시 | Piper Jaffray | Overweight |
모두보기
Cellectis Adr 주식(CLLS)의 최신 뉴스
European Stocks Shine As ADRs Climb Higher - Finimize
European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com
Cellectis S.A. announces board change and meeting By Investing.com - Investing.com India
Cellectis S.A. announces board change and meeting - Investing.com
European Equities See Growth In US Trade - Finimize
Cellectis earnings beat by $0.07, revenue topped estimates - Investing.com
Cellectis earnings beat by $0.06, revenue topped estimates - Investing.com India
Cellectis Charts Course For 2025 With Boost From AstraZeneca Deal - Barchart.com
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
Cellectis stock touches 52-week low at $1.14 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
Cellectis’s SWOT analysis: biotech firm’s stock faces CAR T challenges - Investing.com
Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% By Investing.com - Investing.com South Africa
Cellectis stock touches 52-week low at $1.2 amid market challenges - Investing.com India
Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% - Investing.com India
What Recent Market Trends Mean for Cosan S.A ADR’s (CSAN) Stock - The News Heater
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Cellectis stock touches 52-week low at $1.24 amid market challenges - Investing.com India
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS) - MarketBeat
Cellectis earnings missed by $0.20, revenue fell short of estimates - Investing.com
Cellectis stock touches 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Cellectis stock touches 52-week low at $1.4 amid market challenges - Investing.com India
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
This Penny Stock Has 270% Upside Potential In 2025. Is It A Buy Now? - Barchart
Analysts Predict 400% Upside Potential for This Penny Stock - Yahoo Finance
Cellectis stock plunges to 52-week low at $1.52 amid market challenges - Investing.com
Cellectis stock touches 52-week low at $1.7 amid market challenges - Investing.com
Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year - Investing.com
Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year ahead - Investing.com
Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com
CellectisADR (CLLS) Price Target Increased by 7.35% to 11.62 - Nasdaq
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature
Biotech Stocks Rise After FDA Halts Test By Rival Blood Cancer Firm Cellectis - Investor's Business Daily
Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U
Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U
Cellectis Adr (CLLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.50%
자본화:
|
볼륨(24시간):